Envoy inks research deal with Merck

Jupiter, FL-based Envoy Therapeutics says it has struck a multi-year research collaboration deal with an affiliate of Merck to discover novel diabetes and obesity drug targets. Envoy will use its bacTRAP technology to identify proteins expressed specifically in certain cell types. Merck will then work to identify and develop compounds that modulate protein targets with therapeutic potential for the treatment of metabolic disorders. Envoy gets an upfront fee and research funds. Envoy release

Suggested Articles

Argenx’s phase 3 data set the bar for rival FcRn assets in development at Alexion, Immunovant and UCB.

Tufts scientists discovered that two anti-seizure drugs can lessen the development of brain defects caused by nicotine exposure in frogs.

Merck will apply its vaccine capabilities to an asset based on Themis’ measles vector platform that is set to enter the clinic this year.